Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMPVRN9)

Drug Name

Setmelanotide Drug Info

Synonyms

RM-493; UNII-N7T15V1FUY; BIM-22493; N7T15V1FUY; 920014-72-8; Setmelanotide [USAN:INN]; GTPL9272; CHEMBL3301624; CS-6399; DB11700; HY-19870; L-Cysteinamide, N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-> 8)-disulfide; (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-d

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Approved	[1]
Bardet biedl syndrome	5A61.0	Phase 3	[2]
Prader-Willi syndrome	LD90.3	Phase 2	[3]
Diabetic complication	5A2Y	Preclinical	[4]

Cross-matching ID

PubChem CID: 11993702
CAS Number: CAS 920014-72-8
TTD Drug ID: DMPVRN9
ACDINA Drug ID: D01425

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Melanocortin receptor 4 (MC4R)	TTD0CIQ	MC4R_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Melanocortin receptor 4 (MC4R)	DTT	MC4R	5.904	5.009	4.548	4.597

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Obesity

ICD Disease Classification

5B81

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Melanocortin receptor 4 (MC4R)	DTT	MC4R	5.64E-01	-0.04	-0.18

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	ClinicalTrials.gov (NCT03746522) Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alstrom Syndrome (AS) Patients With Moderate to Severe Obesity. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	2011 Pipeline of Ipsen.